Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
As long-acting injectables near approval, daily pill versions of the same drugs show long-term benefit.
Cabotegravir plus rilpivirine maintenance therapy worked equally well when taken monthly or every two months.
Recently, ViiV Healthcare applied for approval of the first long-acting injectable HIV regimen.
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
The experimental long-acting injectable regimen of cabotegravir and rilpivirine stands poised for approval.
Given every four weeks, the combo injection of cabotegravir and Edurant (rilpivirine) will likely face an FDA decision by early 2020.
The trial will investigate whether injections of long-acting cabotegravir and rilpivirine yield a superior rate of viral suppression.
Dosed every four weeks, the injection, which requires a clinic visit, includes long-acting rilpivirine and cabotegravir.
The Conference on Retroviruses and Opportunistic Infections in Seattle saw many important studies that are advancing the fight against HIV.
Participants in a study were started on daily oral drugs and then half were switched over to long-acting meds.
Given every four weeks, combo injections of cabotegravir and rilpivirine will likely face an FDA decision by early 2020.
Promising findings from a study of a two-drug injectable treatment given every four weeks.
The company has released new data from a trial of injectable cabotegravir and Edurant given every four or eight weeks.
ViiV Healthcare has reported promising one-year findings from a study of a two-drug injectable treatment given every four weeks.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.